Materials and methods
All chemicals were purchased at the purest grade commercially available and were used without further purification. Cyclen was purchased from Strem, France. Bromoethylamine hydrogen bromide, bromopropylamine hydrobromide, tert-butyl bromoacetate, N-methylpyrollidinone (dry), pyridine, H4BAPTA, acetic anhydride and N,N-dimethylformamide (extra dry) were purchased from Sigma-Aldrich, Germany. Toluene, acetonitrile, dichloromethane and methanol were purchased as analytical grade solvents from Acros Organics, Germany. Lanthanide(III) chlorides were prepared by dissolving metal(III) oxides (Aldrich) in a slight excess of HCl (Carlo Erba, 37%) followed by evaporation of solvents and dissolution in H2O.
High-performance liquid chromatography (HPLC) was performed at room temperature using a Varian (Australia) PrepStar instrument equipped with a PrepStar 335 photodiode array detector at 254 nm. Reversed-phase analytical HPLC was performed in a stainless steel ChromSep (length 250 cm, internal diameter 4.6 mm, outside diameter 3/8 in. and particle size 8 μm) C18 column (Varian). The ligands were purified using the following gradient:
-
Method A: 40% solvent A (methanol) and 60% solvent B (water) to 100% solvent B in 5 min running isocratically at 100% solvent B for 10 min and then to 60% solvent B in the next 2 min.
-
Method B: 95% solvent A (acetonitrile, 0.1% HCOOH) and 5% solvent B (water, 0.1% HCOOH) to 70% solvent B in 10 min and then 100% in the next 8 min running isocratically for 12 min after that and then to 5% in next 2 min.
The flow rate used for analytical HPLC was 1 mL min−1 and for preparative 65 mL min−1. All solvents used were HPLC grade filtered through a 0.45-μm nylon-66 Millipore filter prior to use.
1H and 13C NMR spectra were recorded using a Bruker 400 MHz spectrometer (1H—internal reference CDCl3 at 7.27 ppm or D2O at 4.75 ppm; 13C—internal reference CDCl3 at 77.0 ppm or tetramethylsilane at 0 ppm). All the experiments were performed at 298 K. Electrospray ionization (ESI) low-resolution mass spectrometry (LRMS) spectra were obtained using an SL 1100 system (Agilent, Germany) with ion-trap detection in positive and negative ion mode. IR spectra were recorded with a Nicolet Impact 400 D spectrometer using neat compounds as disks with KBr and only the major bands were noted. UV–vis spectra of 5D0 ← 7F0 transitions of Eu2L1 were obtained with a PerkinElmer Lambda 19 spectrometer in the region 577–581 nm with data steps of 0.05 nm [26]. The concentrations of the samples were approximately 0.02 M and the temperature dependence was measured in the interval 288–323 K in the absence and presence of Ca2+. To maintain a constant temperature, thermostatizable cells with a 10-cm optical length were used. The luminescence measurements were performed with a Varian Eclipse spectrofluorimeter, equipped with a 450-W xenon arc lamp, a microsecond flash lamp and a red-sensitive photomultiplier (300–850 nm). The luminescence spectra were obtained after excitation of the 5L6 ← 7F0 band (394 nm). An aqueous solution (0.02 M) of Eu2L1 was measured at 298 K in the absence and presence of Ca2+.
The 1H NMRD profiles were recorded at the Laboratory of Inorganic and Bioinorganic Chemistry, Ecole Polytechnique Fédérale de Lausanne, Switzerland, using a Stelar Spinmaster FFC fast-field-cycling relaxometer covering magnetic fields from 2.35 × 10−4 to 0.47 T (proton Larmor frequency range 0.01–20 MHz). The temperature was controlled by a VTC90 temperature control unit and fixed by a gas flow. At higher fields, the relaxivity was recorded using Bruker Minispecs mq30 (30 MHz), mq40 (40 MHz) and mq60 (60 MHz), on a Bruker 4.7 T (200 MHz) cryomagnet connected to a Bruker Avance 200 console and with a Bruker Avance 500 spectrometer (500 MHz). The temperature was measured by a substitution technique [27] or via a preliminary calibration using methanol and ethylene glycol standards [28]. The longitudinal (1/T
1) and transverse (1/T
2) 17O NMR relaxation rates were measured in the temperature range 277–344 K. The data were recorded using a Bruker Avance 500 (11.75 T, 67.8 MHz) spectrometer. The temperature was calculated according to a previous calibration with ethylene glycol and methanol [28]. The samples were measured in 5-mm NMR tubes and were enriched with tert-butanol to allow for the bulk magnetic susceptibility correction [29]. The 1/T
1 data were obtained by the inversion recovery method, while the 1/T
2 data were measured by the Carr–Purcell–Meiboom–Gill spin-echo technique. Acidified water (HClO4, pH 3.8) was used as an external reference. Analyses of the 17O NMR and 1H NMRD experimental data were performed with the Visualiseur/Optimiseur programs running on a MATLAB platform version 6.5 [30, 31].
Synthesis
Compound 4a was synthesized according to a previously reported procedure [32]. With use of an analogous method, compound 4b was synthesized via 3b from the substrate 1b [33].
Compound 3b. 1H NMR (CDCl3, 400 MHz), δ (ppm): 6.97–6.84 (m, 5H), 4.65 (s, 2H), 2.98–2.89 (m, 2H), 2.86–2.70 (m, 5H), 2.70–2.60 (m, 3H), 2.58–2.17 (m, 7H), 2.16–1.75 (m, 9H), 1.32 (br s, 2H), 1.06–1.03 (m, 27H). 13C NMR 172.2, 171.2, 155.2, 152.9, 135.6, 127.1, 126.4, 81.3, 81.0, 65.7, 64.7, 55.4, 50.3, 48.9, 38.5, 37.8, 28.2, 26.7, 26.5, 25.2. ESI–MS m/z: [M + H]+ calcd for C37H63N5O8, 705.5; found, 706.5.
Compound 4b. 1H NMR (CDCl3, 400 MHz), δ (ppm): 8.19 (br s, 2H), 3.42–2.99 (m, 8H), 2.85–2.20 (m, 16H), 1.61 (br s, 2H), 1.41 (s, 27H). 13C NMR (CDCl3, 100 MHz), δ (ppm): 172.0, 169.8, 81.8, 81.1, 57.2, 55.9, 50.1, 49.4, 48.9, 38.5, 27.2, 27.1, 22.9. ESI–MS m/z: [M + H]+ calcd for C29H57N5O6, 571.4; found, 572.4 .
General method for the synthesis of compounds 6a and 6b
Compound 4a or 4b (2 mmol) was dissolved in 5 mL of dry N-methylpyrollidinone with 50 μL of dry Et3N and heated at 333 K for 15 min. Anhydride 5 [34] was then added to this reaction mixture (295 mg, 0.67 mmol) in small lots under N2. After complete addition of 5, the solution was kept under continuous stirring at 333 K overnight. It was then evaporated, dissolved in dichloromethane and extracted with water. The organic layer was collected and evaporated to get a yellow oil. The crude product was then purified by reversed-phase HPLC using method A to get a light yellow fluffy solid.
1,2-Bis{[2-{[({1-[1,4,7-tris(tert-butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane-10-yl]eth-2-yl}amino)carbonyl]methyl}-(carboxymethyl)amino]phenoxy}ethane, 6a. Yield: 573 mg (55%) 1H NMR (CDCl3, 400 MHz), δ (ppm): 7.01–6.98 (m, 2H), 6.92–6.89 (m, 2H), 6.77–6.74 (m, 4H), 4.56 (d, J = 6.4 Hz, 2H, CHHO), 4.34 (d, J = 15.5 Hz, 2H, CHHCONH), 4.01 (d, J = 17.8 Hz, 2H, CHHCOOH), 3.91 (d, J = 6.4 Hz, 2H, CHHO), 3.48 (d, J = 17.8 Hz, 2H, CHHCOOH), 3.36–3.21 (m, 22H), 3.08–2.80 (m, 12H), 2.78–2.69 (m, 6H), 2.76–2.56 (m, 18H), 1.47 (s, 36H), 1.43 (s, 18H). 13C NMR (CDCl3, 100 MHz), δ (ppm): 175.2 (CONH), 175.0 (CONH), 170.2, 170.1, 149.4, 139.2, 120.6, 119.5, 115.4, 112.1, 81.8, 81.5, 66.4 (CH2O), 60.7 (NCH2CONH), 58.5 (CH2COOH), 56.5, 54.8, 53.5, 51.3, 50.3, 49.7, 47.8, 32.1 (CH2
CH2CONH), 29.6, 28.1. ESI–MS m/z: [M + H]+ calcd for C78H130N12O20, 1,554.9; found, 1,555.9.
1,2-Bis{[3-{[({1-[1,4,7-tris(tert-butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane-10-yl]prop-3-yl}amino)carbonyl]methyl}-(carboxymethyl)amino]phenoxy}ethane, 6b. Yield: 424 mg (40%). 1H NMR (CDCl3, 400 MHz), δ (ppm): 7.08–7.06 (m, 2H), 6.91–6.89 (m, 2H), 6.85–6.82 (m, 4H), 4.49 (br s, 2H), 4.31 (br s, 4H), 4.08–3.73 (m, 8H), 3.57–3.09 (m, 20H), 3.04–2.47 (m, 32H), 2.40 (br s, 4H), 2.01 (br s, 2H), 1.53 (s, 18H), 1.48 (s, 36H). 13C NMR (CDCl3, 100 MHz), δ (ppm): 175.7, 173.4, 170.9, 170.2, 150.2, 139.8, 120.3, 120.2, 115.7, 112.2, 82.2, 82.0, 66.6, 61.0, 58.7, 56.5, 55.3, 49.6, 49.1, 47.6, 35.5, 28.6, 28.4, 22.2. ESI–MS m/z: [M + H]+ calcd for C80H134N12O20, 1,582.9; found, 1,584.0.
General method for the synthesis of L1 and L2
Neat trifluoroacetic acid (70 mL) was added to the previously obtained compound 6a or 6b (0.32 mmol) and the reaction was kept at room temperature for 24 h. Trifluoroacetic acid was then evaporated, and the residue was dried under vacuum and purified by reversed-phase HPLC using method B.
1,2-Bis{[2-{[({1-[1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane-10-yl]eth-2-yl}amino)carbonyl]methyl}-(carboxymethyl)amino]phenoxy}ethane, L1. Yield: 220 mg (60%). 1H NMR (CDCl3, 400 MHz), δ (ppm): 7.06–6.99 (m, 4H), 6.94 (t, J = 7.0 Hz, 2H), 6.87–6.85 (m, 2H), 4.27 (s, 4H), 3.83 (s, 4H), 3.77 (s, 4H), 3.58 (br s, 8H), 3.45 (s, 4H), 3.28–3.12 (m, 24H), 3.02–2.97 (m, 4H), 2.82–2.75 (m, 12H). 13C NMR (D2O, 100 MHz), δ (ppm): 177.6, 174.7, 170.5, 169.9, 150.1, 138.9, 122.5, 121.4, 117.4, 113.0, 67.0, 57.9, 56.7, 56.1, 55.3, 51.0, 50.6, 50.5, 49.2, 47.6, 33.5. IR (cm−1): 3,426 (vs), 2,964 (m), 2,929 (m), 2,860 (m), 1,718 (s), 1,637 (vs), 1,384 (s), 1,355 (s), 1,328 (m), 1,240 (s), 1,203 (s), 762 (m), 694 (m). ESI–MS m/z: [M−H]− calcd for C54H82N12O20, 1,218.57; found, 1,217.7.
1,2-Bis{[3-{[({1-[1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane-10-yl]prop-3-yl}amino)carbonyl]methyl}-(carboxymethyl)amino]phenoxy}ethane, L2. Yield: 126 mg from 400 mg of 6b (40%). 1H NMR (D2O, 400 MHz), δ (ppm): 6.98–6.91 (m, 4H), 6.88 (t, J = 7.4, 2H), 6.82–6.80 (m, 2H), 4.20 (s, 4H), 3.78 (s, 4H), 3.74 (s, 4H), 3.57 (s, 4H), 3.39–3.31 (m, 8H), 3.27–3.20 (m, 8H), 3.13–2.92 (m, 20H), 2.89–2.83 (m, 8H), 2.65 (br s, 4H), 1.61–1.53 (m, 4H). 13C NMR (D2O, 100 MHz), δ (ppm): 177.7, 174.4, 149.9, 138.5, 122.3, 121.5, 117.4, 113.2, 67.1, 57.6, 56.2, 56.1, 55.4, 50.9, 50.5, 49.6, 49.2, 36.4, 22.6. ESI–MS m/z: [M−H]− calcd for C56H86N12O20, 1,246.6; found, 1,245.6.
Preparation of solutions of lanthanide(III) complexes
The complexes used for 1H and 17O relaxometric and UV–vis measurements were prepared by mixing a slight excess (5%) of the ligand solution with the appropriate lanthanide(III) chloride solution. The pH was adjusted to 7 using KOH solution and the reaction mixture was stirred at 323 K overnight. The absence of free Ln3+ was checked by xylenol orange indicator in HCl/urotropine buffer (pH 5.8). For each Gd2L sample, the Gd3+ concentration was determined by measuring the bulk magnetic susceptibility shifts [35].
Gd2L1. ESI–LRMS m/z: [M−H + Na]− calcd for C78H124Gd2N12O20, 1,525.1; found, 1,547.6. IR: 3,448 (vs), 1,602 (vs), 1,560 (s), 1,400 (m), 1,323 (m), 1,242 (m), 1,203 (vs), 1,085 (m), 762 (m), 723(m).
Eu2L1. ESI–LRMS m/z: [M−H]− calcd for C54H76Eu2N12O20, 1,156.4; found 1,155.5.
Gd2L2. ESI–LRMS m/z: [M + H]+ calcd for C56H80Gd2N20O12, 1,553.1; found, 1,553.6.
Relaxometric Ca2+ titrations of Gd2L1 and Gd2L2
The titrations were performed at 11.75 T, 298 K and pH 7.3 [maintained by N-(2-hydroxyethyl)piperazine-N′-ethanesulfonic acid buffer]. A solution of CaCl2 of known concentration was added stepwise to the complex solution and the longitudinal proton relaxation time T
1 was measured after each Ca2+ addition. The initial Gd3+ concentrations were 7.4 and 4.0 mM for Gd2L1 and Gd2L2, respectively. The relaxivity r
1 was calculated from Eq. 1, using the actual Gd3+ concentration at each point of the titration:
$$ \frac{1} {{T_{1,{\rm obs}} }} = \frac{1} {{T_{1,{\rm d}} }} + r_1 \left[ {{\text{Gd}}} \right], $$
(1)
where T
1,obs is the observed longitudinal relaxation time, T
1,d is its diamagnetic contribution in the absence of the paramagnetic substance and [Gd] is the concentration of Gd3+.
Relaxometric Mg2+ titration of Gd2L1
The titration was done analogously to the Ca2+ titration (B = 11.75 T, 298 K; initial Gd3+ concentration of 2.6 mM). When the Mg2+-to-complex ratio was 23 (in the Ca2+ titration, the plateau was already reached at this Ca2+-to-Gd2L1 ratio), a Ca2+ solution was added stepwise and the relaxivity was measured.